Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)

a study on Cardiac Arrest Induced Hypothermia Brain Hypoxia Hypoxia

Summary

Eligibility
for people ages up to 17 years (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around
Principal Investigator
by Anil Sapru, MD

Description

Summary

This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest.

The study team hypothesizes that longer durations of cooling may improve either the proportion of children that attain a good neurobehavioral recovery or may result in better recovery among the proportion already categorized as having a good outcome.

Keywords

Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain, Bayesian Adaptive Clinical Trial, Hypothermia, therapeutic, Coma, Pediatric, Brain Ischemia, Brain Hypoxia-Ischemia, Heart Arrest, Out-of-Hospital Cardiac Arrest, Hypoxia, Hypothermia, Therapeutic Hypothermia, Cooling 0 hours, Cooling 12 hours, Cooling 18 hours, Cooling 24 hours, Cooling 36 hours, Cooling 48 hours, Cooling 60 hours, Cooling 72 hours, Cooling 84 hours, Cooling 96 hours

Eligibility

You can join if…

Open to people ages up to 17 years

  • Age 2 days to < 18 years with corrected gestational age of at least 38 weeks
  • Chest compressions for at least 2 minutes
  • Coma or encephalopathy after resuscitation from Out-of-Hospital Cardiac Arrest (OHCA)
  • Requires continuous mechanical ventilation through endotracheal tube or tracheostomy
  • Definitive temperature control device initiated
  • Randomization within 6 hours of Return of Spontaneous Circulation (ROSC)
  • Informed consent from Legally Authorized Representative (LAR) including intent to maintain life support for 120 hours

You CAN'T join if...

  • Glasgow Coma Motor Score (GCMS) = 6
  • LAR does not speak English or Spanish
  • Duration of Cardiopulmonary Resuscitation (CPR) > 60 minutes
  • Severe hemodynamic instability with continuous infusion of epinephrine or norepinephrine of 2 micrograms per kilogram per minute (μg/kg/minute) or initiation of Extracorporeal membrane oxygenation (ECMO)
  • Pre-existing severe neurodevelopmental deficits with Pediatric Cerebral Performance Category (PCPC) =5 or progressive degenerative encephalopathy
  • Pre-existing terminal illness, unlikely to survive to one year
  • Cardiac arrest associated with brain, thoracic, or abdominal trauma
  • Active and refractory severe bleeding prior to randomization
  • Extensive burns or skin lesions incompatible with surface cooling
  • Planned early withdrawal of life support before 120 hours
  • Sickle cell anemia
  • Pre-existing cryoglobulinemia
  • Non-fatal drowning in ice covered water
  • Central nervous system tumor with ongoing chemotherapy
  • Previous enrollment in P-ICECAP trial
  • Prisoner
  • Chronic hypothermia
  • New post-cardiac arrest diabetes insipidus
  • Pregnancy

Locations

  • University of California Los Angeles (UCLA) Mattel Children's Hospital accepting new patients
    Los Angeles California 90095 United States
  • Children's Hospital of Los Angeles accepting new patients
    Los Angeles California 90027 United States
  • Memorial Health - Miller Children's and Women's Hospital of Long Beach accepting new patients
    Long Beach California 90806-1701 United States

Lead Scientist at UCLA

  • Anil Sapru, MD
    Professor, Pediatrics, Medicine. Authored (or co-authored) 148 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of Michigan
Links
Sign up for this study
ID
NCT05376267
Study Type
Interventional
Participants
Expecting 900 study participants
Last Updated
Contact us about this trial